Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-126853 · Präparat HOS-096317
Hypersensitivity reactions/anaphylaxis In the pivotal trial CLEOPATRA in metastatic breast cancer, the overall frequency of investigator reported hypersensitivity/anaphylaxis events during the entire treatment period was 9.3% in the placebo-treated group and 11.3% in the Perjeta-treated group, of which 2.5% and 2.0% were NCI-CTCAE Grade 3-4, respectively. Overall, 2 patients in the placebo-treated group and 4 patients in the Perjeta-treated group experienced events described as anaphylaxis by the investigator (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 2cf4e1555cec5e848f59c68f7664c57942c6d6c3bca3f14536615c03ddbcf730 · Zeichen 11998–12531 im Abschnitt